We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amylyx (AMLX) Doses First Patient in Wolfram Syndrome Study
Read MoreHide Full Article
Amylyx Pharmaceuticals, Inc. (AMLX - Free Report) announced that the first participant has been dosed in the HELIOS study of pipeline candidate AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO]) for the treatment of Wolfram syndrome (WS). Shares were up 3.80% following the news.
HELIOS, a phase II study, is an exploratory open-label proof of biology study evaluating the effect of AMX0035 safety and tolerability and various measures of endocrinological, neurological and ophthalmologic function.
Top-line results from the study are expected in 2024.
WS, a rare progressive disease, is an autosomal recessive neurodegenerative disease characterized by childhood-onset diabetes, optic nerve atrophy and neurodegeneration.
The recently published preclinical data demonstrated initial proof-of-concept for the therapeutic development of AMX0035 (sodium phenylbutyrate and taurursodiol) in WS. Data also showed that a combination treatment of two chemicals may restore cellular functioning in a cellular model of WS.
We note that the FDA granted orphan drug designation to AMX0035 for the treatment of WS in November 2020.
In the year so far, the stock has plunged 19.5% against the industry’s 0.1% gain.
Image Source: Zacks Investment Research
Amylyx received a significant boost in 2022 as the FDA finally approved its drug for the treatment of adults with amyotrophic lateral sclerosis (ALS) under the brand name Relyvrio (sodium phenylbutyrate and taurursodiol).
The marketing authorization application (MAA) for the drug for the treatment of ALS is under review with the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The company now expects an opinion from CHMP by mid-year.
Some well-placed stocks in the overall healthcare sector are Novo Nordisk (NVO - Free Report) and Ligand Therapeutics (LGND - Free Report) , both sporting a Zacks Rank #1 at present.
In the past 30 days, estimates for Novo Nordisk’s 2023 earnings per share have risen from $4.20 to $4.43 and estimates for 2024 have gone up by 29 cents to $5.19.
Ligand’s earnings per share estimates for 2023 increased to $4.32 from $3.30 in the past 30 days. LGND beat earnings estimates in one of the last four reported quarters and missed in the remaining three.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Amylyx (AMLX) Doses First Patient in Wolfram Syndrome Study
Amylyx Pharmaceuticals, Inc. (AMLX - Free Report) announced that the first participant has been dosed in the HELIOS study of pipeline candidate AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO]) for the treatment of Wolfram syndrome (WS). Shares were up 3.80% following the news.
HELIOS, a phase II study, is an exploratory open-label proof of biology study evaluating the effect of AMX0035 safety and tolerability and various measures of endocrinological, neurological and ophthalmologic function.
Top-line results from the study are expected in 2024.
WS, a rare progressive disease, is an autosomal recessive neurodegenerative disease characterized by childhood-onset diabetes, optic nerve atrophy and neurodegeneration.
The recently published preclinical data demonstrated initial proof-of-concept for the therapeutic development of AMX0035 (sodium phenylbutyrate and taurursodiol) in WS. Data also showed that a combination treatment of two chemicals may restore cellular functioning in a cellular model of WS.
We note that the FDA granted orphan drug designation to AMX0035 for the treatment of WS in November 2020.
In the year so far, the stock has plunged 19.5% against the industry’s 0.1% gain.
Image Source: Zacks Investment Research
Amylyx received a significant boost in 2022 as the FDA finally approved its drug for the treatment of adults with amyotrophic lateral sclerosis (ALS) under the brand name Relyvrio (sodium phenylbutyrate and taurursodiol).
The marketing authorization application (MAA) for the drug for the treatment of ALS is under review with the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The company now expects an opinion from CHMP by mid-year.
Zacks Rank & Stocks to Consider
Amylyx currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Some well-placed stocks in the overall healthcare sector are Novo Nordisk (NVO - Free Report) and Ligand Therapeutics (LGND - Free Report) , both sporting a Zacks Rank #1 at present.
In the past 30 days, estimates for Novo Nordisk’s 2023 earnings per share have risen from $4.20 to $4.43 and estimates for 2024 have gone up by 29 cents to $5.19.
Ligand’s earnings per share estimates for 2023 increased to $4.32 from $3.30 in the past 30 days. LGND beat earnings estimates in one of the last four reported quarters and missed in the remaining three.